These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

863 related items for PubMed ID: 21709196

  • 1. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY.
    J Clin Oncol; 2011 Aug 01; 29(22):3050-5. PubMed ID: 21709196
    [Abstract] [Full Text] [Related]

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec 01; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
    Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP.
    J Clin Oncol; 2013 Nov 10; 31(32):4085-91. PubMed ID: 24101040
    [Abstract] [Full Text] [Related]

  • 5. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):670-6. PubMed ID: 19836157
    [Abstract] [Full Text] [Related]

  • 6. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.
    Br J Neurosurg; 2013 Aug 01; 27(4):430-5. PubMed ID: 23418781
    [Abstract] [Full Text] [Related]

  • 7. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.
    J Neurooncol; 2011 Apr 01; 102(2):311-6. PubMed ID: 20686820
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.
    J Clin Oncol; 2010 Jun 01; 28(16):2712-8. PubMed ID: 20439646
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
    Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA.
    Neuro Oncol; 2014 Sep 01; 16(9):1255-62. PubMed ID: 24670608
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
    Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA.
    J Clin Oncol; 2009 Sep 01; 27(25):4155-61. PubMed ID: 19636006
    [Abstract] [Full Text] [Related]

  • 16. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.
    J Clin Oncol; 2008 May 01; 26(13):2192-7. PubMed ID: 18445844
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY.
    Clin Cancer Res; 2009 Jan 01; 15(1):330-7. PubMed ID: 19118062
    [Abstract] [Full Text] [Related]

  • 18. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, Wirtz CR, Coburger J.
    Clin Neurol Neurosurg; 2018 Apr 01; 167():6-10. PubMed ID: 29425743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.